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Abstract
Background: Intravenous hydration during percutaneous coronary intervention (PCI) significantly 
reduces the risk of contrast-induced nephropathy (CIN), but there are no well-defined protocols regard-
ing the optimal hydration volume (HV) required to prevent CIN following emergent PCI. Therefore, this 
study investigates the association between the intravenous HV and CIN after emergent PCI.
Methods: 711 patients were prospectively recruited who had underwent emergent PCI with hydration 
at routine speed and the relationship was investigated between HV or HV to weight ratio (HV/W) and 
the CIN risk, which was defined as a ≥ 25% or ≥ 0.5 mg/dL increase in serum creatinine levels from 
baseline within 48–72 h of exposure to the contrast.
Results: The overall CIN incidence was 24.7%. Patients in the higher HV quartiles had elevated CIN 
rates. Multivariate analysis showed that higher HV/W ratios were not associated with a decreased 
risk (using the HV) of CIN, but they were associated with an increased risk (using the HV/W) of CIN  
(Q4 vs. Q1: adjusted odds ratio 1.99; 95% confidence interval 1.05–3.74; p = 0.034). A higher HV/W 
ratio was not significantly associated with a reduced risk of long-term death (all p > 0.05).
Conclusions: The data suggests that a higher total HV is not associated with a decreased CIN risk or 
beneficial long-term prognoses, and that excessive HV may increase the risk of CIN after emergent PCI. 
(Cardiol J 2017; 24, 6: 660–670)
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Introduction
Contrast-induced nephropathy (CIN), which 
is a common complication following percutaneous 
coronary intervention (PCI), is associated with 
in-hospital and long-term morbidity and mortality, 
especially in high-risk patients undergoing emer-
gent PCI [1–3] and hydration is the most effective 
method used to prevent CIN [4, 5]. Adequate 
intravenous administration of normal saline signifi-
cantly reduced CIN risk in patients who underwent 
primary PCI (adequate hydration vs. no hydration: 
11% vs. 21%) [6]. Furthermore, a higher hydration 
volume (HV) has been associated with a signifi-
cant trend towards a lower incidence of CIN [7]. 
However, no benefit existed in patients who were 
undergoing primary PCI and were administered 
more aggressive hydration [8].
Therefore, no well-defined protocols have 
been established regarding the optimal total HV 
and hydration duration for CIN prevention fol-
lowing emergent PCI. Since the hydration rate 
has been based on body weight (W) (1 mL/kg/h) 
in previous studies [6–9], we investigated the 
associations between the HV adjusted according 
to W (HV/W, mL/kg) and the risk of CIN after 
emergent PCI.
Methods
This prospective observational study reviewed 
all consecutive patients who were candidates for 
emergent PCI between January 2010 and Decem-
ber 2013, using the institutional protocol described 
in a previous study [9]. In accordance with the 
updated guidelines [10], the study’s exclusion cri-
teria were pregnancy, lactation, the intravascular 
administration of a contrast medium within 7 days 
before the procedure or 3 days post-operatively 
(n = 129), not using low-osmolarity contrast 
agents (n = 150), not undergoing emergent PCI 
(n = 2890), cardiovascular surgery or endovas-
cular repair (n = 384), end-stage renal disease or 
renal replacement (n = 9), missing pre- or post-
operative creatinine data (n = 188), the presence of 
malignancies (n = 3), not using isotonic saline for 
hydration (n = 28), and missing weight data (n = 1). 
Finally, 711 patients with ST-elevation myocardial 
infarction (STEMI) or those with non-ST-elevation 
acute coronary syndrome (NSTE-ACS) who were 
very high risk and underwent emergent PCI were 
included in the analysis (Fig. 1) [11]. 
Trained nurses carefully monitored and re-
corded the follow-up events through office visits 
and telephone interviews at 1, 6, 12, 24, and 
36 months after the emergent PCI. The mean 
follow-up duration was 2.38 ± 3.52 years (median 
2.08 years; interquartile range [IQR] 1.65–3.58 
years). The institution’s ethics research committee 
approved the study, and all patients gave their writ-
ten informed consent to participate in this study.
Emergent PCI was defined as primary PCI 
for patients with STEMI and immediate PCI, that 
is, < 2 h from hospital admission and analogous 
to STEMI management, for very high-risk pa-
tients with NSTE-ACS [11]. Emergent PCI was 
performed using standard guide catheters, guide 
wires, balloon catheters, and stents that were 
inserted via the femoral or radial approaches. The 
contrast medium dose administered was left to the 
discretion of the interventional cardiologist. All pa-
tients received non-ionic, low-osmolarity contrast 
agents, either Iopamiron or Ultravist, both of which 
contain 370 mg iodine/mL. The medications and 
invasive treatments were administered according 
to the American College of Cardiology Foundation/
American Heart Association guidelines [12]. In ac-
cordance with the local institutional protocol [9], 
the serum creatinine concentrations were meas-
ured in all patients on their admission to hospital, 
and on days 1, 2, and 3 after the emergent PCI.
The creatinine clearance (CrCl) was calculated 
by applying the Cockcroft-Gault formula to the 
serum creatinine concentrations [13]. All patients 
received continuous intravenous infusions of 
isotonic saline, either at a rate of 1 mL/kg/h or at 
a rate of 0.5 mL/kg/h for cases with left ventricular 
ejection fractions (LVEF) of < 40% or severe 
congestive heart failure, which were initiated at or 
immediately before the emergent PCI procedure 
and continued for 4–24 h after the procedure. The 
HV/W ratios were calculated using the HV and W.
The primary endpoint was CIN25, which was 
defined as an increase in the serum creatinine level 
by ≥ 25% or ≥ 0.5 mg/dL from baseline within 72 h 
of contrast exposure [14]. Other CIN definitions 
included CIN0.5, which was defined as an increase 
of ≥ 0.5 mg/dL in the serum creatinine level from 
baseline within 72 h of contrast exposure [15] and 
CIN0.3, which was defined as an increase of ≥ 50% 
or ≥ 0.3 mg/dL in the serum creatinine level from 
baseline within 48 h of contrast exposure [16].  Also 
followed up on and recorded were in-hospital clini-
cal outcomes, which included renal replacement 
therapy, acute heart failure, re-infarctions, the use 
of intra-aortic balloon pumps (IABP), arrhythmias, 
strokes, bleeding, and death, and long-term major 
adverse clinical events (MACE), which included 
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death, non-fatal myocardial infarction, target vessel 
revascularisation, CIN requiring renal replacement 
therapy, stroke, and re-hospitalisation.
Statistical analysis
For the continuous variables, one-way analy-
ses of variance were conducted for the normally 
distributed data, which are expressed as the means 
± standard deviations, and the Kruskal-Wallis test 
was used to analyse the data with non-normal 
distributions, these are presented as medians and 
the IQR. Pearson’s c2 or Fisher’s exact tests were 
used, as appropriate, to analyse the categorical 
variables, which are expressed as percentages. 
After trade-offs between over fitting and ensur-
ing the unbalanced factors were well controlled, 
factors were used with p values of < 0.05 in the 
baseline analyses and the clinically important fac-
tors for multivariate logistic regression. Propensity 
score analysis was used for sensitivity analysis to 
compare CIN among groups. The Kaplan-Meier 
method and log-rank test were used to compare 
mortality and MACE rates according to the HV/W 
quartiles. In addition, multivariate Cox regression 
analyses, which were adjusted for age, a CrCl of 
< 60 mL/min, an LVEF < 40%, anemia, diabetes 
mellitus, hypertension, and other factors, were 
conducted. The data were analysed on an available 
case basis, and patients with missing data were not 
included in the analysis. All of the data analyses 
were performed using SAS statistical software, 
version 9.4 (SAS Institute Inc., Cary, NC, USA) 
and R software, version 3.1.2 (The R Foundation 
for Statistical Computing Vienna, Austria; http://
www.R-project.org/) [17]. A two-sided p value 
< 0.05 was considered statistically significant. 
Results
Baseline characteristics
The patients (n = 711) had a mean age of 
62.21 ± 12.30 years, and there were 576 men who 
comprised 81% of the study population. 676 (95.1%) 
patients were diagnosed with STEMI. All patients 
who underwent emergent PCI were stratified into 
the following quartiles based on their HV/W ratios: 
Figure 1. Flow chart of patients who underwent emergent percutaneous coronary intervention (PCI); CIN — contrast 
induced nephropathy; MACE — major adverse clinical events; HV/W — hydration volume to weight ratio; AMI — 
acute myocardial infarction; IABP — intra-aortic balloon pump.
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quartile (Q)1: < 8.30 mL/kg; Q2: 8.30–13.30 mL/kg; 
Q3: 13.30–19.00 mL/kg; and Q4: > 19.00 mL/kg. 
Patients with higher HV/W quartiles were signifi-
cantly older, had worse renal functions, had lower 
LVEF, higher contrast volumes and Mehran risk 
scores, and they used more IABP and diuretics, but 
fewer angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers (Tables 1, 2).
Table 1. Baseline patient characteristics according–the hydration volume–body weight ratio (HV/W) 
quartiles.
Characteristic HV/W quartiles P for  
trend
Q1 (n = 154) 
< 8.30  
mL/kg
Q2 (n = 200) 
8.30–13.30  
mL/kg
Q3 (n = 179) 
13.30–19.00  
mL/kg
Q4 (n = 178) 
> 19.00  
mL/kg
Sex, male 133 (86.4%) 166 (83.0%) 140 (78.2%) 137 (77.0%) 0.103
Age [years] 58.47 ± 11.55 62.44 ± 11.37 62.67 ± 12.11 64.79 ± 13.39 < 0.001
Age > 75 years 14 (9.1%) 30 (15.0%) 28 (15.6%) 45 (25.3%) < 0.001
Weight [kg] 70.33 ± 9.71 64.69 ± 9.71 64.07 ± 11.10 59.42 ± 11.15 < 0.001
STEMI 144 (94.1%) 192 (96.0%) 168 (93.9%) 171 (95.1%) 0.66
Non-STEMI 9 (5.9%) 8 (4.0%) 11 (6.1%) 7 (4.9%) 0.66
Systolic BP [mm Hg] 125.51 ± 20.69 124.28 ± 20.57 121.50 ± 22.51 119.00 ± 23.55 0.028
LVEF [%] 55.25 ± 10.17 54.62 ± 9.95 54.19 ± 11.24 51.85 ± 11.10 0.025
LVEF < 40% 9 (6.5%) 16 (8.5%) 23 (13.9%) 21 (12.7%) 0.113
CHF 19 (12.4%) 51 (25.5%) 49 (27.4%) 52 (29.2%) 0.002
Post-IABP 6 (3.9%) 17 (8.5%) 18 (10.1%) 27 (15.2%) 0.006
Mehran score 4.28 ± 3.75 5.37 ± 4.36 5.89 ± 5.10 7.57 ± 5.80 < 0.001
Medical history:
Diabetes mellitus 31 (20.1%) 47 (23.5%) 37 (20.7%) 34 (19.1%) 0.747
Smoker 75 (48.7%) 89 (44.5%) 76 (42.5%) 82 (46.1%) 0.706
Hypertension 64 (41.6%) 101 (50.8%) 91 (50.8%) 94 (52.8%) 0.179
Hypotension 1 (0.6%) 11 (5.5%) 16 (8.9%) 27 (15.2%) < 0.001
Hyperlipidemia 24 (15.6%) 39 (19.5%) 35 (19.6%) 31 (17.4%) 0.746
Prior MI 8 (5.2%) 10 (5.0%) 15 (8.4%) 6 (3.4%) 0.208
History of CABG 0 (0.0%) 0 (0.0%) 1 (0.6%) 0 (0.0%) 0.395
Medication:
ACEI/ARB 145 (94.2%) 184 (92.0%) 157 (87.7%) 141 (79.2%) < 0.001
Beta-blocker 136 (88.3%) 166 (83.0%) 136 (76.0%) 129 (72.5%) 0.001
CCB 15 (9.8%) 26 (13.1%) 16 (8.9%) 13 (7.3%) 0.287
Diuretics 40 (26.0%) 53 (26.5%) 84 (46.9%) 81 (45.5%) < 0.001
Laboratory measurements:
Serum creatinine [μmol/L] 87.75 ± 29.93 92.63 ± 35.18 97.06 ± 39.31 106.43 ± 53.02 < 0.001
CrCl [mL/min] 86.54 ± 31.70 71.67 ± 26.91 69.33 ± 31.06 59.74 ± 30.57 < 0.001
CrCl < 60 mL/min 29 (19.3%) 71 (35.9%) 76 (42.5%) 99 (56.6%) < 0.001
LDL-C 3.21 ± 1.11 3.24 ± 1.05 3.27 ± 1.02 3.21 ± 1.13 0.976
HDL-C 0.84 ± 0.25 0.97 ± 0.24 0.80 ± 0.28 0.92 ± 0.36 0.068
TC [mmol/L] 4.93 ± 1.24 5.04 ± 1.14 4.83 ± 1.10 4.88 ± 1.34 0.688
HbA1c [%] 6.67 ± 1.58 6.89 ± 1.54 6.48 ± 1.44 6.74 ± 1.71 0.237
hs-CRP [mg/L] 16.48 ± 24.62 28.89 ± 44.25 30.71 ± 35.45 34.10 ± 37.01 0.077
Anemia 45 (29.6%) 48 (24.0%) 48 (26.8%) 64 (36.2%) 0.063
Hematocrit [%] 41 ± 5 40 ± 5 40 ± 5 39 ± 5 0.031
Data are presented as the means ± standard deviations or as numbers and percentages. ACEI/ARB — angiotensin-converting enzyme inhibi-
tor/angiotensin receptor blocker; BP — blood pressure; CABG — coronary artery bypass grafting; CCB — calcium channel blocker; CHF — 
congestive heart failure; CrCl — creatinine clearance; HbA1c — glycated haemoglobin; HDL-C — high-density lipoprotein cholesterol;  
hs-CRP — high sensitivity C-reactive protein; IABP — intra-aortic balloon pump, LDL-C — low-density lipoprotein cholesterol; LVEF — left  
ventricular ejection fraction; MI — myocardial infarction; STEMI — ST-segment elevation myocardial infarction; TC — total cholesterol
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Table 2. Baseline procedural characteristics of hydration volume–body weight ratio (HV/W) quartiles (Q).
Characteristic HV/W quartiles P for  
trend
Q1 (n = 154) 
< 8.30  
mL/kg
Q2 (n = 200) 
8.30–13.30  
mL/kg
Q3 (n = 179) 
13.30–19.00  
mL/kg
Q4 (n = 178) 
> 19.00  
mL/kg
Diseased coronary lesion 2.08 ± 0.98 2.07 ± 1.31 2.02 ± 0.90 2.22 ± 0.99 0.664
Number of stents 1.15 ± 0.72 1.29 ± 0.72 1.37 ± 0.83 1.34 ± 0.79 0.060
Total length of stent [mm] 30.40 ± 23.06 32.80 ± 18.24 36.23 ± 23.35 35.34 ± 22.95 0.290
Procedure duration [min] 79.42 ± 42.27 76.08 ± 32.49 84.08 ± 51.22 83.82 ± 33.00 0.163
Contrast volume [mL] 120.45 ± 46.56 124.35 ± 46.92 128.99 ± 48.34 129.52 ± 46.23 0.251
Contrast volume > 200 mL 11 (7.1%) 15 (7.5%) 17 (9.5%) 19 (10.7%) 0.605
Hydration volume [mL] 425.45 ± 149.79 674.49 ± 137.65 1027.35 ± 189.39 1741.96 ± 808.48 < 0.001
HV/W [mL/kg] 6.04 ± 2.03 10.43 ± 1.51 16.08 ± 1.66 29.74 ± 13.39 < 0.001
Data are presented as the means ± standard deviations or as numbers and percentages
Table 3. Incidence of contrast-induced nephropathy and in-hospital clinical outcomes according to  
hydration volume–body weight ratio (HV/W) quartiles (Q).
Characteristic HV/W quartiles P for  
trend
Q1 (n = 154) 
< 8.30  
mL/kg
Q2 (n = 200) 
8.30–13.30  
mL/kg
Q3 (n = 179) 
13.30–19.00  
mL/kg
Q4 (n = 178) 
> 19.00  
mL/kg
SCr increase ≥ 0.5 mg/dL 
within 72 h
1 (0.7%) 14 (7.1%) 12 (6.7%) 28 (16.1%) < 0.001
SCr increase ≥ 0.5 mg/dL  
or ≥ 25% within 72 h
28 (18.8%) 48 (24.2%) 40 (22.3%) 57 (32.8%) 0.024
SCr increase ≥ 0.3 mg/dL  
or ≥ 50% within 48 h
12 (8.1%) 25 (13.1%) 20 (11.3%) 43 (24.7%) < 0.001
IABP 6 (3.9%) 18 (9.0%) 19 (10.6%) 27 (15.2%) 0.007
Reinfarction 0 (0.0%) 1 (0.5%) 2 (1.1%) 2 (1.1%) 0.554
Stroke 1 (0.7%) 2 (1.0%) 4 (2.2%) 4 (2.2%) 0.509
Acute heart failure 6 (3.9%) 12 (6.0%) 16 (8.9%) 23 (12.9%) 0.014
Bleeding 0 (0.0%) 1 (0.5%) 3 (1.7%) 12 (6.7%) < 0.001
Death 1 (0.7%) 4 (2.0%) 9 (5.1%) 28 (15.7%) < 0.001
Require RRT 2 (1.3%) 2 (1.0%) 1 (0.6%) 15 (8.4%) < 0.001
Data are presented as numbers and percentages; IABP — intra-aortic balloon pump; RRT — renal replacement therapy; SCr — serum creatinine
Hydration volume to weight ratio for  
predicting contrast-induced nephropathy 
Patients with higher HV had higher CIN rates 
(22.3%, 23.2%, 20.8%, and 31.9% in Q1, Q2, Q3, 
and Q4, respectively; p = 0.063), and patients with 
higher HV/W ratios had significantly higher CIN 
rates (18.8%, 24.2%, 22.3%, and 32.8% in Q1, Q2, 
Q3, and Q4, respectively; p = 0.024). Furthermore, 
the relationships between the HV or HV/W and 
CIN were consistent for different definitions of 
CIN, namely, CIN0.5 and CIN0.3 (Table 3).
Multivariate logistic regression analysis de-
termined that higher HV were not associated with 
a reduced risk (using the HV) of CIN25 (Q2 vs. Q1: 
odds ratio [OR] 1.06; 95% confidence interval [CI] 
0.60–1.85; p = 0.850; Q3 vs. Q1: OR 0.68; 95% CI 
0.38–1.23; p = 0.203; Q4 vs. Q1: OR 1.32; 95% CI 
0.77–2.26; p = 0.308) (Table 4), but they were as-
sociated with an increased risk (using the HV/W) 
of CIN25 (Q4 vs. Q1: OR 1.99; 95% CI 1.05–3.47; 
p = 0.034) (Table 4). Being female, aged > 75 years, 
the CrCl, and IABP and diuretic use were inde-
pendent predictors of CIN25 (Table 5).
In-hospital clinical outcomes
In-hospital MACE occurred in 142 patients 
(20.0%). Forty-two (5.9%) patients died and 20 
(2.8%) patients required dialysis. Patients with 
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Table 4. Univariate analyses and multivariate associations between contrast-induced nephropathy25 
and the hydration volume (HV) to body weight (W) ratio quartiles (Q).
Risk factors Univariate logistic regression Multivariate logistic regression
OR 95% CI P OR 95% CI P
HV/W ratio Q2 vs. Q1 1.38 0.82–2.34 0.225 1.63 0.89–2.99 0.113
HV/W ratio Q3 vs. Q1 1.24 0.72–2.14 0.430 1.15 0.61–2.17 0.665
HV/W ratio Q4 vs. Q1 2.11 1.25–3.54 0.005 1.99 1.05–3.74 0.034
Woman 2.27 1.52–3.40 < 0.001 2.84 1.72–4.71 < 0.001
Age > 75 years 2.13 1.39–3.24 < 0.001 2.49 1.44–4.31 0.001
CrCl 1.00 1.00–1.01 0.645 1.02 1.01–1.02 < 0.001
Anemia 1.15 0.79–1.68 0.451 1.09 0.69–1.71 0.716
Diabetes mellitus 1.02 0.67–1.55 0.919 0.96 0.60–1.55 0.871
Smoking 0.88 0.62–1.24 0.458 1.20 0.78–1.87 0.408
Prior MI 1.77 0.90–3.49 0.098 1.57 0.72–3.43 0.259
Hypotension 2.01 1.13–3.56 0.017 1.17 0.58–2.40 0.658
LVEF 0.97 0.95–0.99 0.001 0.98 0.96–1.00 0.058
Use of IABP 3.57 2.16–5.92 < 0.001 2.88 1.53–5.43 0.001
Contrast volume 1.00 1.00–1.01 0.109 1.00 1.00–1.01 0.184
Number of stents 1.00 0.80–1.25 0.982 0.95 0.74–1.24 0.725
Use of diuretics 1.78 1.25–2.52 0.001 1.65 1.08–2.50 0.019
Use of ACEI/ARB 0.60 0.37–0.98 0.043 0.82 0.44–1.52 0.525
Use of b-blocker 0.60 0.40–0.89 0.011 0.81 0.49–1.33 0.399
ACEI/ARB — angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CI — confidence interval; CrCl — creatinine clearance; 
HV/W — hydration volume to body weight ratio; IABP — intra-aortic balloon pump; LVEF — left ventricular ejection fraction; MI — myocardial 
infarction; OR — odds ratio
Table 5. Univariate analyses and multivariate associations between contrast-induced nephropathy25 
and hydration volume (HV) ratio quartiles (Q).
Risk factor Univariate logistic regression Multivariate logistic regression
OR 95% CI P OR 95% CI P
HV ratio Q2 vs. Q1 1.06 0.64–1.75 0.834 1.06 0.60–1.85 0.850
HV ratio Q3 vs. Q1 0.92 0.55–1.52 0.739 0.68 0.38–1.23 0.203
HV ratio Q4 vs. Q1 1.63 1.03–2.58 0.036 1.32 0.77–2.26 0.308
Woman 2.27 1.52–3.40 < 0.001 3.00 1.81–4.97 < 0.001
Age > 75 years 2.13 1.39–3.24 < 0.001 2.47 1.43–4.29 0.001
CrCl 1.00 1.00–1.01 0.645 1.01 1.01–1.02 < 0.001
Anemia 1.15 0.79–1.68 0.451 1.04 0.66–1.62 0.873
Diabetes mellitus 1.02 0.67–1.55 0.919 0.99 0.62–1.60 0.973
Smoking 0.88 0.62–1.24 0.458 1.21 0.78–1.87 0.392
Prior MI 1.77 0.90–3.49 0.098 1.51 0.69–3.31 0.300
Hypotension 2.01 1.13–3.56 0.017 1.25 0.61–2.56 0.544
LVEF 0.97 0.95–0.99 0.001 0.98 0.96–1.00 0.053
Use of IABP 3.57 2.16–5.92 < 0.001 2.86 1.52–5.36 0.001
Contrast volume 1.00 1.00–1.01 0.109 1.00 1.00–1.01 0.171
Number of stents 1.00 0.80–1.25 0.982 0.97 0.75–1.26 0.839
Use of diuretics 1.78 1.25–2.52 0.001 1.62 1.07–2.46 0.023
Use of ACEI/ARB 0.60 0.37–0.98 0.043 0.83 0.44–1.55 0.554
Use of b-blocker 0.60 0.40–0.89 0.011 0.77 0.47–1.27 0.301
ACEI/ARB — angiotensin-converting enzyme inhibitors or angiotensin receptor blocker; CI — confidence interval; CrCl — creatinine clearance; 
IABP —intra-aortic balloon pump; LVEF — left ventricular ejection fraction; MI — myocardial infarction; OR — odds ratio
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Figure 2. Kaplan-Meier curves for the cumulative probability of mortality and major adverse clinical events (MACE). 
A. Kaplan-Meier curves for the cumulative probability of mortality, B. Kaplan-Meier curves for the cumulative prob-
ability of MACE; HV/W — hydration volume to weight ratio.
elevated HV or HV/W ratios were more likely to 
experience MACE, which included acute heart 
failure (Q1: 3.9%; Q2: 6.0%; Q3: 8.9%; and Q4: 
12.9%; p = 0.014), dialysis (p < 0.001), and in-
hospital mortality (Q1: 0.7%; Q2: 2.0%; Q3: 5.1%; 
and Q4: 15.7%; p < 0.001) (Table 3).
Follow-up clinical outcomes
Median follow-up duration for this study co-
hort was 2.08 years (IQR 1.65–3.58 years). Kaplan-
-Meier curve analyses revealed that higher HV/W 
ratios were significantly associated with increased 
risk of mortality (p < 0.001) and MACE (p = 0.005) 
(Fig. 2A, B). None of the patients in Q1 died. 
Cox proportional hazards modeling showed that 
after adjusting for confounding clinical factors 
that included hypertension, a CrCl < 60 mL/min, 
use of diuetic bleeding, Mahran score and LVEF, 
the higher HV/W ratios were not associated with 
reduced risk of all-cause mortality (Q4 vs. Q2: 
adjusted hazard ratio 1.60; 95% CI 0.80 to 3.22; 
p = 0.184) and MACE (p > 0.05) (Fig. 3A, B). 
Patients with CIN25 had increased risk of all-
cause mortality (Kaplan-Meier analysis p = 0.001; 
Cox regression analysis p = 0.003) and MACE 
(Kaplan-Meier analysis p = 0.001; Cox regression 
analysis p < 0.001) (Figs. 4, 5).
Discussion
The present study is the first to investigate 
the potential benefit of a higher HV in preventing 
CIN after emergent PCI when there is not enough 
time to administer pre-procedural hydration. It 
was found that even after adjusting for other risk 
confounders, patients with higher HV that had 
been adjusted according to their weight (HV/W 
ratios) did not appear to have lower risk for CIN 
or beneficial long-term prognoses. In addition, an 
excessive HV appeared to increase the risk of CIN 
after emergent PCI.
Patients undergoing emergent PCI procedures 
often have renal risk factors, including hypoten-
sion, shock, large volumes of contrast media 
administered, and the impossibility of starting 
renal prophylactic therapy [3] and they were also 
likely to present with reduced cardiac outputs and 
hypotension induced by myocardial infarction, 
and depletions in intravascular volume caused by 
vomiting, diaphoresis, or reduced oral intakes [7], 
which are associated with an increased risk of CIN 
[3, 7]. The cumulative incidence of CIN was as high 
as 24.7% in the present study.
Intravenous hydration can inhibit the renin–an-
giotensin system and vasopressin, and it increased 
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Figure 4. Multivariate Cox regression analysis indicated that higher hydration volume to body weight ratios were as-
sociated with increasing trends in all-cause mortality and major adverse clinical events (MACE). A. Multivariate Cox 
regression analysis for all-cause mortality, B. Multivariate Cox regression analysis for MACE; CI — confidence interval; 
CIN — contrast induced nephropathy; HR — hazard ratio; LVEF — left ventricular ejection fraction.
Figure 3. Multivariate Cox regression analysis indicated that higher hydration volume to body weight ratios were as-
sociated with increasing trends in all-cause mortality and major adverse clinical events (MACE). A. Multivariate Cox 
regression analysis for all-cause mortality, B. Multivariate Cox regression analysis for MACE; CI — confidence interval; 
CrCl — creatinine clearance; HR — hazard ratio; LVEF — left ventricular ejection fraction.
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the urinary flow rate, reduced the concentration of 
the contrast medium in the tubules, and it expe-
dited the excretion of the contrast medium, thereby 
reducing the length of time that the tubular cells 
were exposed to the toxic effects of the contrast 
medium [18]. Maioli et al. [7] assigned patients 
to the following HV tertiles: 1st tertile: ≤ 900 mL; 
2nd tertile: 901–1080 mL; and 3rd tertile: ≥ 1081 mL, 
and they demonstrated a significant trend between 
lower CIN incidence rates and increasing HV, with 
contrast-induced acute kidney injury (CI-AKI) 
rates of 26.7%, 17%, and 8.1%, respectively, and 
an HV ≤ 960 mL was the optimal cut-off point for 
predicting the risk of CI-AKI. However, different 
agents, namely, saline and bicarbonate, were used 
for hydration, and normal saline is more readily 
available in emergent clinical practice, accord-
ingly this study analysed the association between 
the saline HV and CIN, but consistent benefits of 
higher HV were not evident. 
Negative results in the present study are 
consistent with those reported from studies on 
patients with chronic kidney disease in which 20 h 
of pre-procedural hydration with 1 mL/kg/h isotonic 
saline was similar to 5 h of pre-procedural hydration 
in relation to the prevention of CIN [19] and 24 h 
of hydration before plus 48 h of hydration after the 
procedure with 1 mL/kg/h isotonic saline (high-
dose group 5334 ± 783 mL) did not appear to pro-
vide additional benefits in terms of CIN prevention 
compared with 12 h of hydration before plus 12 h of 
hydration with 1 mL/kg/h isotonic saline (low-dose 
group 1893 ± 270 mL) after coronary procedures 
[20]. Given the short post-procedural half-lives of 
contrast media, short-term peri-procedural hydra-
tion rather than long-term hydration could be more 
effective at reducing the risk of CIN [21]. Following 
the short period of hydration required for the clear-
ance of contrast medium, continuous long-term 
hydration may have no additional benefits in the 
prevention of CIN.
Findings of a recent study have also shown 
that a higher saline HV (1085 ± 168 mL vs. 
941 ± 148 mL) did not reduce the rate of CI-AKI (19% 
vs. 19.2%) following primary angioplasty, even with 
rapid hydration before the procedure [8]. These 
findings are similar to those from the present study 
in which similar patients underwent emergent 
procedures. Experimental studies have established 
that contrast media induce dose-dependent and 
time-dependent renal cell injuries [22]. If renal cell 
toxicity begins a few minutes after the cells have 
been exposed to the contrast medium, it can be 
speculated that even high HV initiated simultane-
ously might be insufficient to counter the cytotoxic 
effects of the contrast medium.
In patients within the higher HV/W quartiles 
in the present study, the higher risk of CIN seemed 
to correlate strongly with the more harmful clini-
cal characteristics that included older age, lower 
Figure 5. Kaplan-Meier curves for the cumulative probability of mortality and major adverse clinical events (MACE). 
A. Kaplan-Meier curves for the cumulative probability of mortality, B. Kaplan-Meier curves for the cumulative prob-
ability of MACE; CIN — contrast induced nephropathy.
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LVEF and CrCl, a higher frequency of congestive 
heart failure, diabetes, emergent PCI, and higher 
contrast volumes. However, higher HV/W ratios 
seemed to be associated with an increasing trend 
of CIN incidence even after adjusting for the above 
confounding variables. Indeed, an excessive HV 
seems to increase the risks of CIN and poor clini-
cal outcomes by mechanisms that are not yet fully 
understood. An excessive HV that is administered 
at a standard speed may increase the risk of heart 
failure, which may lead to overload volumes or 
increases in the preloads, lower cardiac outputs, 
and inadequate renal perfusion, as it occurs in car-
diorenal syndrome, which, in turn, may increase 
the venous pressure, leading to kidney congestion, 
activation of the renin–angiotensin–aldosterone 
system, and marked alterations in immune and 
somatic cell signalling [23, 24]. Hence, it is likely 
that higher HV administered at average speeds 
did not have any benefits in relation to prevention 
of CIN or patient prognoses. In the present study 
however, the rates of hydration were reduced by 
half in cases with an LVEF of < 40% or in those 
with severe congestive heart failure. Moreover, the 
so-called force diuresis may be another factor of 
renal function deterioration after contrast medium 
exposure. As mentioned above, an excessive HV 
may lead to overload volumes. To avoid excessive 
positive fluid balance, diuretics were more common 
use in patients with higher HV, as shown in the 
results of our study (from Q1 to Q4, 26.0 vs. 26.5 
vs. 46.9 vs. 45.5%, p < 0.001). Indeed, previous 
clinical studies demonstrated that the prophylactic 
furosemide appears to increase CIN rate in patients 
without adequate matching between hydration 
and urine flow [25, 26]. Drastically forced diuresis 
induced reduction of blood circulation volume and 
dehydration, which may deteriorate renal hemody-
namics and activate renin–angiotensin system [27]. 
As a result, the contrast induced kidney was 
exacerbated. 
Recently, peri-procedural, short–term, and 
rapid hydration with normal saline has demon-
strated remarkable benefits with respect to reduc-
ing the CIN risk [28, 29]. Shorter peri-procedural 
hydration effectively reduces the viscosity of the 
urine, which, in turn, may accelerate the excretion 
of the contrast medium [30, 31]. Hence, rather than 
administering fluid at an average rate over a long 
period of time, more rapid hydration may help to 
attenuate the increase in urine viscosity caused 
by the administration of contrast medium, thereby 
aiding contrast medium excretion and shortening 
the exposure time of the tubular cells to contrast 
medium. Further randomized studies are needed 
to clarify the relationship between the HV and CIN 
after emergent PCI.
Limitations of the study
The current study has several limitations. 
First, this prospective observational study was 
conducted at a single centre; therefore, baseline 
deviation existed inevitably (such as men compris-
ing 81% of the study population) and the evidence 
may not be as robust as that obtained from a rand-
omized, controlled trial. Second, CrCl was obtained 
using the Cockcroft-Gault formula rather than by 
undertaking direct measurements. Third, varia-
tions in the times at which the measurements were 
undertaken may have missed the post-procedural 
peak creatinine levels. Finally, data that described 
patient oral water intakes were absent; hence, the 
inability to investigate whether patients with low 
HV drank more water and achieved higher HV 
that were potentially similar to those administered 
higher intravenous HV.
Conclusions
In conclusion, the data suggests that higher 
HV achieved through the administration of normal 
saline at a standard speed and adjusted according to 
W showed no benefit in relation to the prevention 
of CIN or in relation to long-term prognosis after 
emergent PCI, but excessive hydration appeared 
to be associated with an increased risk of CIN in 
patients undergoing emergent PCI. Randomised 
studies are needed to clarify the relationship be-
tween the HV and CIN after emergent PCI.
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